Population Trends in Aspirin Use for Cardiovascular Disease Prevention 1980–2009: The Minnesota Heart Survey
Open Access
- 1 December 2015
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 4 (12)
Abstract
Background: Daily low‐dose aspirin is recommended for primary prevention of myocardial infarction and stroke in higher‐risk patients. Population trends in aspirin use for cardiovascular disease (CVD) prevention in an urban population (Minneapolis/St. Paul, 2010 population 2.85 million) from 1980 to 2009 were evaluated. Methods and Results: Surveys of randomly selected adults aged 25 to 74 years were collected at 5‐year intervals. Self‐reports of regular aspirin use for CVD prevention and history of CVD were obtained. Six cross‐sectional surveys included 12 281 men and 14 258 women. Age‐adjusted aspirin use for primary prevention increased during this period from 1% to 21% among men and 1% to 12% among women. Aspirin use was highest in those aged 65 to 74 years. For secondary prevention, age‐adjusted aspirin use increased from 19% to 74% among men and 11% to 64% among women. While data are based on self‐report, a substudy using a biochemical indicator of aspirin use (serum thromboxane B 2 ) supports the validity of self‐report. Conclusions: Aspirin for CVD prevention is commonly used by a large and growing portion of the general population. It is not known if this is based on professional advice or self‐prescribed use. It is also likely that many who would benefit do not use aspirin and others use aspirin inappropriately.Keywords
This publication has 37 references indexed in Scilit:
- Utilization of Secondary Prevention Therapies in Patients With Nonobstructive Coronary Artery Disease Identified During Cardiac CatheterizationCirculation: Cardiovascular Quality and Outcomes, 2010
- Deaths Preventable in the U.S. by Improvements in Use of Clinical Preventive ServicesAmerican Journal of Preventive Medicine, 2010
- Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trialsThe Lancet, 2009
- Aspirin for the Prevention of Cardiovascular Disease: U.S. Preventive Services Task Force Recommendation StatementAnnals of Internal Medicine, 2009
- Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Patients With Type 2 DiabetesA Randomized Controlled TrialJAMA, 2008
- Cost-Effectiveness of Aspirin Treatment in the Primary Prevention of Cardiovascular Disease Events in Subgroups Based on Age, Gender, and Varying Cardiovascular RiskCirculation, 2008
- Aspirin Use Among Adults Aged 40 and Older in the United StatesAmerican Journal of Preventive Medicine, 2007
- The discovery of aspirin's antithrombotic effects.2007
- Aspirin for the Primary Prevention of Cardiovascular Events in Women and MenJAMA, 2006
- Trends in Blood Pressure, Hypertension Control, and Stroke Mortality: The Minnesota Heart SurveyThe American Journal of Medicine, 2006